Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Xenical Patient Compliance Could Increase With New DTC Campaign

Executive Summary

Roche will attempt to increase patient compliance for its obesity drug Xenical through a multi-faceted direct-to-consumer campaign.

You may also be interested in...



Roche Xenical Patient Retention Program Is Key To Sales Growth

Roche has set up a Xenical patient retention program in the U.S. in a continuing effort to improve the obesity drug's sales record.

Roche Xenical Patient Retention Program Is Key To Sales Growth

Roche has set up a Xenical patient retention program in the U.S. in a continuing effort to improve the obesity drug's sales record.

Roche U.S. CEO Zenner Retiring In January; Successor Not Yet Named

Roche is varying from its decades long pattern of carefully choreographed management transitions by leaving open the succession plan for U.S. CEO Patrick Zenner.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel